BRAF/MEK inhibitors (BRAFi/MEKi) and PD-1 and CTLA-4 immune checkpoint inhibitors (ICI) have revolutionized malignant melanoma treatment and improved patients’ clinical outcome significantly. The gene discussed is CTLA4; the disease is melanoma.